# EDITORIAL

# Cardiac autonomic control in health and disease

Kalyanam Shivkumar and Jeffrey L. Ardell

UCLA Cardiac Arrhythmia Center and Neurocardiology Research Center of Excellence, Los Angeles, CA, USA

Email: kshivkumar@mednet.ucla.edu

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide (Mozaffarian et al. 2015; Oliveira et al. 2015). What is becoming increasingly self-evident is that the progression of cardiovascular disease is dependent upon the interplay between the autonomic nervous system and the peripheral target tissues it regulates (Chen et al. 2014; Florea & Cohn, 2014; Fukuda et al. 2015). It is further recognized that there are inherent (e.g. genetic) and acquired factors (e.g. myocardial infarction) that impact the disease process (Zucker et al. 2012; Fukuda et al. 2015). Anatomical structure sets the foundation for function and a thorough understanding of these relationships, from the subcellular to integrated whole body neurohumoral control, is required for the development of cardiovascular therapies that have a strong mechanistic foundation.

Neuromodulation-based therapeutics for cardiovascular disease is an evolving science with profound implications for management of cardiac arrhythmias, heart failure and hypertension. Cardiac sympathetic denervation/decentralization (Bourke et al. 2010; Vaseghi et al. 2014) and bioelectric medicine (De Ferrari, 2014; Buckley et al. 2015; Zipes, 2015) targeted to 'nexus points' of the cardiac nervous system have already shown significant therapeutic promise. The importance of this area of science was the impetus for us to host the UCLA Autonomic Nervous System Control of the Heart in Health and Disease Symposium, first in 2012 and the second on 12 and 13 March 2015. These meetings were supported in part by the generous donations provided by the Leonetti O'Connell Family Foundation. The 2 day workshop had five major themes and 20 presentations. The themes were: (1) Functional Neuroanatomy of the Heart, (2) Neurohumoral Adaptations to Chronic Heart Disease, (3) The Role of the Autonomic Nervous System in Cardiac Arrhythmogenesis,
(4) Pre-clinical Neurocardiology, and
(5) Clinical Neurocardiology. For those interested in viewing specific presentations from these symposia, these can be found at http://dgsom.ucla.edu/streaming/cacsymposium/.

This special issue of The Journal of Physiology presents a synthesis of the primary themes, preclinical to clinical, that were brought forth in the 2015 meeting. It includes three white papers that summarize the current state of understanding for 'Molecular and Cellular Neurocardiology' (Habecker et al. 2016), 'Translational (pre-clinical) Neurocardiology' (Ardell et al. 2016), and 'Clinical Neurocardiology' (Shivkumar et al. 2016). These white papers represent the combined efforts of 39 leading international experts in the field and highlight the cellular, organ level and clinical aspects of neurocardiology. They summarize data derived from normal and pathological states. These papers also provide mechanistic insights into several emerging applications of autonomic regulation therapy for cardiovascular diseases

In addition to the three white papers in this issue there is a special editorial on 'Neurocardiology - a neurobiologist's perspective' by Professor Jänig (2016). There are additional papers focusing on major aspects of autonomic neural processing and the neural-cardiac interface in normal and pathological states. At the level of the cardiomyocyte, alterations in excitation-contraction coupling, substrate utilization and receptor signalling are considered in normal vs. pathological conditions (Gloschat et al. 2016). At the level of peripheral autonomic ganglia, alterations in cyclic nucleotide pathways are discussed in relation to neurotransmitter release (Kalla et al. 2016; Li & Paterson, 2016). Consequences for peripheral neural network control of cardiac electrical and mechanical function is presented with a primary focus on neural transduction of cardiac pathology relative to heart failure and arrhythmias (Ardell et al. 2016). Relevant aspects of spinal cord, brainstem and higher centre processing are also brought to the forefront, especially as they relate to 'interoception' (Shivkumar

*et al.* 2016). This series of papers also highlights many important aspects of cardiac control that are conserved across species or not (Gloschat *et al.* 2016). Ultimately our objective is to translate these findings to the human conditions. It is also critical for future studies to deploy existing methodologies in a physiological context (Joyner, 2016) and to evolve new biomarkers for assessing disease state and therapeutic interventions.

While it is always tempting to simplify regulation for system analysis, the evolving history of neurocardiology repeatedly demonstrates that the processing capabilities of the autonomic nervous system starting from neural networks on the heart and continuing all the way to subcortical regions are quite complex and nuanced. Sensory transduction is a fundamental link that traverses all levels of the neuraxis and ultimately translates into closed-loop reflex control of the heart. Alterations in neural processing and amplification of sympathoexcitation arising as a result of the transduction and transmission of afferent impulses from the peripheral to the central aspects of the cardiac nervous system are a major cause of cardiovascular disease progression (Ardell et al. 2016; Habecker et al. 2016; Shivkumar et al. 2016). Evolving new therapeutic approaches to manage such neural and cardio-neural substrate changes is a major impetus for this field.

In conclusion we hope that many more curious and bright minds will enter this field and also learn to embrace its complexity. The multi-disciplinary approaches that are outlined in this issue point to a new therapeutic dimension. Neuromodulationbased strategies provide unique opportunities to develop meaningful therapies for the tens of millions who are going to die suddenly from arrhythmias or suffer serious morbidity and ultimate death due to heart failure in the coming years!

# References

Ardell JL, Andresen MC, Armour JA, Billman GE, Chen P-S, Foreman R, Herring N, O'Leary DS, Sabbah HN, Schultz HD, Sunagawa K & Zucker IH (2016).
Translational Neurocardiology: preclinical models and cardioneural integrative aspects. *J Physiol* **594**, 3877–3909.

Bourke T, Vaseghi M, Michowitz Y, Sankhla V, Shah M, Swapna N, Boyle NG, Mahajan A, Narasimhan C, Lokhandwala Y & Shivkumar K (2010). Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. *Circulation* **121**, 2255–2262.

Buckley U, Shivkumar K & Ardell JL (2015). Autonomic regulation therapy in heart failure. *Curr Heart Fail Rep* **12**, 284–293.

Chen PS, Chen LS, Fishbein MC, Lin SF & Nattel S (2014). Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res* **114**, 1500–1515.

- De Ferrari GM (2014). Vagal stimulation in heart failure. *J Cardiovasc Transl Res* 7, 310–320.
- Florea VG & Cohn JN (2014). The autonomic nervous system and heart failure. *Circ Res* 114, 1815–1826.

Fukuda K, Kanazawa H, Aizawa Y, Ardell JL & Shivkumar K (2015). Cardiac innervation and sudden cardiac death. *Circ Res* 116, 2005–2019.

- Gloschat CR, Koppel AC, Aras KK, Brennan JA, Holzem KM & Efimov IR (2016). Arrhythmogenic and metabolic remodelling of failing human heart. *J Physiol* **594**, 3963–3980.
- Habecker BA, Anderson ME, Birren SJ, Fukuda K, Herring N, Hoover DB, Kanazawa H, Paterson DJ & Ripplinger CM (2016).
  Molecular and cellular neurocardiology: development, cellular and molecular adaptations to heart disease. J Physiol 594, 3853–3875.
- Jänig W (2016). Neurocardiology: a neurobiologist's perspective. J Physiol 594, 3955–3962.
- Joyner MJ (2016). Preclinical and clinical evaluation of autonomic function in humans. *J Physiol* **594**, 4009–4013.

# Editorial

- Kalla M, Chotalia M, Coughlan C, Hao G, Crabtree MJ, Tomek J, Bub G, Paterson DJ & Herring N (2016). Protection against ventricular fibrillation via cholinergic receptor stimulation and the generation of nitric oxide. J Physiol 594, 3981–3992.
- Li D & Paterson DJ (2016). Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness. *J Physiol* **594**, 3993–4008.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2015). Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131, e29-e322.
- Oliveira GB, Avezum A & Roever L (2015). Cardiovascular disease burden: evolving knowledge of risk factors in myocardial infarction and stroke through population-based research and perspectives in global prevention. *Front Cardiovasc Med* **2**, 32.
- Shivkumar K, Ajijola O, Anand A, Armour JA, Chen P-S, Esler M, De Ferrari GM, Fishbein MC, Goldberger J, Harper RK, Joyner MJ, Khalsa SS, Kumar R, Lane R, Mahajan A, Po S, Schwartz P, Somers V, Valderrabano M, Vaseghi M & Zipes DP (2016). Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol 594, 3911–3954.

- Vaseghi M, Gima J, Kanaan C, Ajijola OA, Marmureanu A, Mahajan A & Shivkumar K (2014). Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. *Heart Rhythm* 11, 360–366.
- Zipes DP (2015). Antiarrhythmic therapy in 2014: Contemporary approaches to treating arrhythmias. *Nat Rev Cardiol* **12**, 68–69.
- Zucker IH, Patel KP & Schultz HD (2012). Neurohumoral stimulation. *Heart Fail Clin* **8**, 87–99.

#### **Additional information**

## **Competing interests**

None declared.

# Author contributions

Both authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

#### Funding

NHLBI HL084261 to K.S.; U18 EB021799 to J.L.A.